Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results (Q35214141)

7 August 2017

Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results (English)

1 reference

7 August 2017

1 reference

1 reference

1 reference

Robert L Murphy

17

0 references

Chakra Budhathoki

object named as

Chakra Budhathoki

6

0 references

Paul E Sax

1

object named as

Paul E Sax

1 reference

7 August 2017

3

Ann C Collier

1 reference

7 August 2017

18

Margaret A Fischl

1 reference

7 August 2017

4

Eric S Daar

1 reference

7 August 2017

Camlin Tierney

2

1 reference

7 August 2017

Katie Mollan

5

1 reference

7 August 2017

Catherine Godfrey

7

1 reference

7 August 2017

Nasreen C Jahed

8

1 reference

7 August 2017

Laurie Myers

9

1 reference

7 August 2017

David Katzenstein

10

1 reference

7 August 2017

Awny Farajallah

11

1 reference

7 August 2017

James F Rooney

12

1 reference

7 August 2017

Belinda Ha

13

1 reference

7 August 2017

William C Woodward

14

1 reference

7 August 2017

Judith Feinberg

15

1 reference

7 August 2017

Karen Tashima

16

1 reference

7 August 2017

AIDS Clinical Trials Group Study A5202 Team

19

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 October 2011

1 reference

Journal of Infectious Diseases

7 August 2017

1 reference

7 August 2017

204

1 reference

7 August 2017

8

1 reference

7 August 2017

1191-1201

1 reference

Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel

7 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Suboptimal adherence to darunavir/ritonavir has minimal effect on efficacy compared with lopinavir/ritonavir in treatment-naive, HIV-infected patients: 96 week ARTEMIS data

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

HLA-B*5701 screening for hypersensitivity to abacavir

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Impact of human immunodeficiency virus type 1 reverse transcriptase inhibitor drug resistance mutation interactions on phenotypic susceptibility

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

A truvada hypersensitivity reaction simulating abacavir hypersensitivity

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients

26 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3173503

Update of the drug resistance mutations in HIV-1: Spring 2008

26 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21917892

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/INFDIS/JIR505

1 reference

7 August 2017

1 reference

7 August 2017

1 reference